The firm gained approval for one acquired program, the ROS1 inhibitor Jideytro, and is expecting another approval for the ALK inhibitor neladalkib this year.

NEW YORK – The European Medicines Agency has given the green light to an investigator-initiated trial of Lantern Pharma's lead drug candidate LP-184 (zirdafulven) for advanced, recurrent bladder ...

The company closed an upsized IPO and concurrent private placement to Sanofi, proceeds of which will fund its pipeline of CRISPR-based medicines.

The firm's oncology unit reported 16 percent growth in Q2, with nearly all oncology medicines reporting revenue growth in the ...

Estrella Immunopharma's first trial of its CD19-directed autologous T-cell therapy for non-Hodgkin's lymphoma is progressing smoothly, the company said late last week, and it has moved on to the dose ...

NEW YORK – Oak Hill Bio on Monday said it plans to go public through a merger with Research Alliance Corporation III (RACC), a special purpose acquisition company (SPAC), and raise funds to develop ...

The company is eyeing deals less than $2 billion, saying it has enough internal assets to replace losses from generic ...

Researchers are exploring delivering super-specific AAVs through the brain's natural waste disposal system, which can carry ...

The anti-amyloid drug is designed for a limited course, where patients can stop treatment once they reach a level of ...

After a promising Phase I read out on mKRAS-VAX in patients with hereditary cancer predisposition and pancreatic lesions, ...

NEW YORK – The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on Friday recommended approval for AstraZeneca and Daiichi Sankyo's HER2-directed antibody-drug ...

Researchers at the Broad Institute, Jackson Laboratory, and Boston Children's Hospital will treat rare disease patients and ...